- Home
- XRAY vs KNSA Comparison
XRAY vs KNSA Comparison
Compare XRAY & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRAY
- KNSA
- Stock Information
- Founded
- XRAY 1899
- KNSA 2015
- Country
- XRAY United States
- KNSA United Kingdom
- Employees
- XRAY N/A
- KNSA N/A
- Industry
- XRAY Medical/Dental Instruments
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- XRAY Health Care
- KNSA Health Care
- Exchange
- XRAY Nasdaq
- KNSA Nasdaq
- Market Cap
- XRAY 2.9B
- KNSA 2.6B
- IPO Year
- XRAY 1987
- KNSA 2018
- Fundamental
- Price
- XRAY $13.53
- KNSA $37.10
- Analyst Decision
- XRAY Hold
- KNSA Strong Buy
- Analyst Count
- XRAY 12
- KNSA 6
- Target Price
- XRAY $19.10
- KNSA $40.83
- AVG Volume (30 Days)
- XRAY 2.7M
- KNSA 431.3K
- Earning Date
- XRAY 11-06-2025
- KNSA 10-28-2025
- Dividend Yield
- XRAY 4.73%
- KNSA N/A
- EPS Growth
- XRAY N/A
- KNSA N/A
- EPS
- XRAY N/A
- KNSA 0.07
- Revenue
- XRAY $3,671,000,000.00
- KNSA $529,332,000.00
- Revenue This Year
- XRAY N/A
- KNSA $37.21
- Revenue Next Year
- XRAY $2.31
- KNSA $11.99
- P/E Ratio
- XRAY N/A
- KNSA $573.99
- Revenue Growth
- XRAY N/A
- KNSA 56.18
- 52 Week Low
- XRAY $12.16
- KNSA $17.82
- 52 Week High
- XRAY $27.48
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- XRAY 40.65
- KNSA 73.54
- Support Level
- XRAY $13.66
- KNSA $35.72
- Resistance Level
- XRAY $14.86
- KNSA $37.25
- Average True Range (ATR)
- XRAY 0.40
- KNSA 0.95
- MACD
- XRAY -0.01
- KNSA 0.14
- Stochastic Oscillator
- XRAY 2.21
- KNSA 94.82
About XRAY DENTSPLY SIRONA Inc.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.